Serial Circulating Tumour Cell Monitoring During Androgen Deprivation and Docetaxel Therapies Identifies Poor Prognostic Metastatic Prostate Cancer
Year: 2026
Type: article
Abstract: Background/Objectives: Adding docetaxel to androgen deprivation therapy (ADT) prolongs survival in metastatic prostate cancer, but not all patients benefit, and no early biomarker identifies individuals with resistant disease. We assessed whether serial circulating tumour cell (CTC) sampling adds prognostic information beyond a pre-treatment sample. Methods: CTCs were enriched by size and deformability (Parsortix®) and phenotyped as epithelial (CK+/VIM−/CD45−), mesenchymal (CK−/VIM+/CD45−), or EMTing (CK+/VIM+/CD45−) at four time points in 61 patients treated with ADT and docetaxel (43 hormone-sensitive; 18 resistant, exploratory). Results: With longer follow-up, our previously reported baseline CTC predictors remained associated with overall survival (OS). In hormone-sensitive patients, baseline ≥ 6 total (HR 3.21, p = 0.007) and epithelial CTCs (p = 0.017) were associated with shorter OS. Across baseline, early, and late treatment, the OS hazard ratio for epithelial CTCs fell (2.59, 2.29, 2.11), yet for ≥3 mesenchymal CTCs rose (1.99, 2.99, 4.08). No single time point result survived false-discovery-rate correction. During early treatment, radiographic responders had fewer mesenchymal CTCs than non-responders (median 0 vs. 2.5, p = 0.032), whereas PSA did not differ (p = 0.642). Persistence of ≥3 mesenchymal CTCs from baseline to late treatment identified the poorest outcome (n = 3; median OS 17.3 months vs. not reached) and survived false-discovery-rate correction (q = 0.019). Late treatment mesenchymal CTCs added value to baseline PSA (p = 0.024) and ALP (p = 0.019) and added potential value to the best baseline marker (≥6 CTCs, p = 0.125), identifying some high-risk patients with baseline < 6 CTCs. Conclusions: Early on-treatment CTC samples may help predict response, while late treatment mesenchymal CTCs may add to baseline clinical markers. These hypothesis-generating findings require validation in a larger prospective cohort.
Source: Cancers
Authors: Caitlin R. Davies, Edwina Burke, Tianyu Guo, Elzbieta Stankiewicz, Lei Xu, Xueying Mao, Glenda Scandura, Prabhakar Rajan, Sarah McCarley, Karen Tipples, Constantine Alifrangis, Akhila G. Wimalasingham, Myria Galazi, Shanthini M. Crusz, Thomas Powles, Alistair Grey, Sakunthala Kudahetti, Greg Shaw, Daniel Berney, Jonathan Shamash, Oleg Blyuss, Yong-Jie Lu
Institutions: Institute of Cancer Research, Queen Mary University of London, Barts Cancer Institute, Gdańsk Medical University, Fudan University, Zhongshan Hospital, Barts Health NHS Trust, University College Hospital, University College London Hospitals NHS Foundation Trust, University College London
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Keywords: circulating tumor cells, metastatic prostate cancer, androgen deprivation therapy, docetaxel, prognostic factors, mesenchymal CTCs, epithelial-mesenchymal transition, overall survival, treatment response monitoring, Parsortix, tumor heterogeneity, hormone-sensitive prostate cancer, treatment resistance
Open Access status: gold
Estimated APC paid: $3,499
Funder: Cancer Research UK
Award: G6792500553
OpenAlex ID: W7235247992
